Nifuroxazide硝呋齐特,965-52-6

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Nifuroxazide

CAS No. : 965-52-6

MCE 国际站：Nifuroxazide

产品活性：Nifuroxazide 是 STAT3 的有效抑制剂，且具有抗癌和抗转移活性。

研究领域：JAK/STAT Signaling  |  Stem Cell/Wnt  |  Anti-infection

作用靶点：STAT  |  Bacterial  |  Antibiotic

In Vitro: When U266 cells are incubated with Nifuroxazide, a significant dose-dependent decrease in STAT3 tyrosine phosphorylation is observed. This inhibition of STAT3 tyrosine phosphorylation is rapid, occurring as early as 1 h after treatment, and is sustained for at least 24 h. Treatment of U266 or INA6 cells with Nifuroxazide for 48 hours result in a dose-dependent loss of cell viability with an EC₅₀ of approximately 4.5 μM in both cell types. Notably, the MM cells lacking constitutive STAT3 activation show little toxicity to Nifuroxazide.

In Vivo: Compared with the vehicle group, treatment with Nifuroxazide could inhibit tumor growth and tumor weight in a dose-dependent manner, with the inhibition rate of tumor volumes being 43.0% and 62.1% at 25 mg/kg and 50 mg/kg, respectively. It is also shown that Nifuroxazide significantly inhibits the proliferation of nuclear Ki-67-positive cells and induces apoptosis cells of cleaved caspase-3-positive cells. Besides, it is found that treatment with Nifuroxazide could inhibit the expression of MMP-2, MMP-9 and p-Stat3 in A375 tumor tissues. What’s more, Nifuroxazide inhibits the infiltration of MDSCs into the lung, which might be associated with suppression of distant colonization of tumor cells in B16-F10 melanoma metastasis model.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Immunology/Inflammation Compound Library  |  JAK/STAT Compound Library  |  Kinase Inhibitor Library  |  Stem Cell Signaling Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Small Molecule Immuno-Oncology Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Antibacterial Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Antibiotics Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Obesity Compound Library  |  Transcription Factor-Targeted Library  |  Anti-Liver Cancer Compound Library   |  FDA-Approved Anticancer Drug Library  |  Anti-Prostate Cancer Compound Library  |  Cancer Stem Cells Compound Library  |  Off-patent Drug Library  |  Cysteine Targeted Covalent Library  |  Mitochondrial Toxicity Compound Library  |  Highly Selective Inhibitors Library  |  Rapamycin  |  Cycloheximide  |  Chloroquine  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Dexamethasone  |  Puromycin dihydrochloride  |  Dimethyl sulfoxide  |  Staurosporine  |  Actinomycin D  |  G-418 disulfate  |  Etoposide  |  5-Azacytidine  |  Cyclosporin A  |  Nigericin sodium salt  |  Brefeldin A  |  Estradiol  |  CCCP  |  Stattic  |  Ionomycin  |  Resveratrol  |  Hygromycin B  |  Tunicamycin  |  Bleomycin sulfate  |  Mitomycin C  |  Everolimus  |  Doxycycline hyclate  |  Tacrolimus  |  Methotrexate

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds